Investigational drug · Phase 3
HS627
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
15
Any phase or sponsor naming "HS627"
First trial start
2020
Jun 28, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS627", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS627" as an intervention, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT07578116 · 562 participants (planned) · Start Mar 9, 2027 · Primary completion May 31, 2032
Drug: Cyclin-Dependent Kinase 4 Inhibitor; Cyclin-Dependent Kinase 6 Inhibitor and 7 more · For: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma; Oligometastatic Breast Carcinoma
Sites: Jonesboro, Arkansas; Derby, Connecticut; Fairfield, Connecticut · 59 sites in all
- TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryPivotal-lookingStatus unknown
Academic and Community Cancer Research UnitedAcademic, hospital or other
NCT04197687 · 480 participants (planned) · Start Feb 20, 2020 · Primary completion Jan 15, 2025
Drug: Multi-epitope HER2 Peptide Vaccine TPIV100; Pertuzumab and 3 more · For: Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7 and 5 more
Sites: Scottsdale, Arizona; Tucson, Arizona; Yuma, Arizona · 30 sites in all
- Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + DocetaxelPivotal-lookingActive, not recruiting
BioRay Pharmaceutical Co., Ltd.Industry
NCT04514419 · 408 participants (planned) · Start Jun 28, 2020 · Primary completion Sep 11, 2024
Drug: HS627; Pertuzumab · For: Breast Cancer
Sites: Qingdao, China
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02003209 · 315 participants · Start Feb 18, 2014 · Primary completion Oct 31, 2016
Drug: Aromatase Inhibition Therapy; Carboplatin and 4 more · For: HER2-Positive Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Stage IB Breast Cancer AJCC v7 and 5 more
Sites: Fairbanks, Alaska; Hot Springs, Arkansas; Anaheim, California · 732 sites in all
- Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerPivotal-lookingTerminated
National Cancer Institute (NCI)NIH
NCT03199885 · 190 participants · Start Apr 5, 2019 · Primary completion Apr 30, 2024
Drug: Atezolizumab; Docetaxel and 3 more · For: Metastatic Breast Adenocarcinoma; Metastatic HER2-Positive Breast Carcinoma; Recurrent Breast Adenocarcinoma and 5 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Gilbert, Arizona · 673 sites in all
- Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single InjectionPivotal-lookingCompleted
BioRay Pharmaceutical Co., Ltd.Industry
NCT05323981 · 180 participants · Start Apr 11, 2022 · Primary completion Oct 9, 2022
Drug: HS627(210mg/7ml); HS627(420mg/14ml) and 1 more · For: Similarity of Pharmacokinetics and Safety
Sites: Qingdao, China
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07407920 · 120 participants (planned) · Start Oct 9, 2025 · Primary completion Sep 30, 2028
Drug: Hormone Therapy; Pembrolizumab and 2 more · For: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Early Stage HER2-Positive Breast Carcinoma and 1 more
Sites: Houston, Texas
The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
NCT04820439 · 88 participants · Start Oct 13, 2020 · Primary completion Feb 1, 2021
Drug: recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627); Perjeta ® · For: Healthy Volunteers
Sites: Qingdao, China
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT06136897 · 35 participants · Start Mar 23, 2017 · Primary completion Nov 3, 2021
Drug: Pertuzumab; Trastuzumab · For: Malignant Solid Neoplasm
Sites: Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- The neuromuscular and autonomic blocking effects of azasteroids containing choline or acetylcholine fragments.
Marshall IG, Harvey AL, Singh H, et al. · J Pharm Pharmacol 1981
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.